Headlines about AngioDynamics (NASDAQ:ANGO) have trended positive recently, according to Accern Sentiment Analysis. Accern rates the sentiment of press coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. AngioDynamics earned a media sentiment score of 0.25 on Accern’s scale. Accern also assigned media coverage about the medical instruments supplier an impact score of 45.8824826308145 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
AngioDynamics (NASDAQ ANGO) traded down 0.967% on Wednesday, hitting $17.915. The company had a trading volume of 18,645 shares. The stock has a market capitalization of $655.33 million, a PE ratio of 130.766 and a beta of 1.14. AngioDynamics has a one year low of $14.80 and a one year high of $18.35. The stock has a 50 day moving average of $16.76 and a 200-day moving average of $16.25.
AngioDynamics (NASDAQ:ANGO) last issued its quarterly earnings data on Tuesday, July 18th. The medical instruments supplier reported $0.19 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.16 by $0.03. The firm had revenue of $86.90 million during the quarter, compared to analyst estimates of $90.72 million. AngioDynamics had a return on equity of 5.19% and a net margin of 2.00%. The business’s quarterly revenue was down 7.0% compared to the same quarter last year. During the same quarter last year, the business posted $0.19 earnings per share. Equities analysts anticipate that AngioDynamics will post $0.67 EPS for the current year.
ANGO has been the subject of several analyst reports. Canaccord Genuity reiterated a “hold” rating and set a $16.50 price objective on shares of AngioDynamics in a report on Wednesday, May 31st. Cantor Fitzgerald lifted their price objective on AngioDynamics from $20.00 to $21.00 and gave the company an “overweight” rating in a report on Tuesday, July 4th. Barclays PLC cut their price objective on AngioDynamics from $17.00 to $16.00 and set an “equal weight” rating on the stock in a report on Wednesday, July 19th. Zacks Investment Research cut AngioDynamics from a “hold” rating to a “sell” rating in a research note on Thursday, July 20th. Finally, BidaskClub cut AngioDynamics from a “hold” rating to a “sell” rating in a research note on Tuesday, August 1st. Five research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $18.60.
COPYRIGHT VIOLATION NOTICE: “AngioDynamics (NASDAQ:ANGO) Receives News Sentiment Rating of 0.25” was first reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of United States and international trademark & copyright laws. The legal version of this article can be read at https://stocknewstimes.com/2017/09/13/favorable-media-coverage-somewhat-unlikely-to-impact-angiodynamics-ango-stock-price.html.
In related news, CEO James C. Clemmer purchased 20,000 shares of the firm’s stock in a transaction dated Thursday, July 20th. The stock was purchased at an average price of $15.64 per share, with a total value of $312,800.00. Following the completion of the purchase, the chief executive officer now owns 86,683 shares of the company’s stock, valued at approximately $1,355,722.12. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO James C. Clemmer acquired 5,000 shares of the business’s stock in a transaction that occurred on Friday, July 21st. The shares were acquired at an average cost of $15.79 per share, for a total transaction of $78,950.00. Following the completion of the acquisition, the chief executive officer now owns 86,683 shares of the company’s stock, valued at $1,368,724.57. The disclosure for this purchase can be found here. In the last ninety days, insiders purchased 25,316 shares of company stock valued at $396,806. 1.88% of the stock is owned by insiders.
AngioDynamics, Inc designs, manufactures and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. The Company’s devices are used in minimally invasive, image-guided procedures.
Receive News & Ratings for AngioDynamics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.